FDA Approves Gilead’s Epclusa for Children with Hepatitis C

The U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ Epclusa for Hepatitis C (HCV) for use in children as young as six years of age or who weigh at least 17 kilograms. The recommended dose of the drug for this age group is based on weight and liver function.